Nexavar Effective in Advanced HCC: Phase III Trial Stopped
Nexavar Effective in Advanced HCC: Phase III Trial Stopped
WEST HAVEN, ConnecticutBayer and Onyx (Emeryville, California) have stopped the phase III SHARP trial of sorafenib (Nexavar) in patients with advanced hepatocellular carcinoma (HCC), based on the recommendation of an independent monitoring committee after interim data showed that the trial had met its primary endpoint. Patients in the Nexavar arm achieved a "superior overall survival," compared to those in the placebo arm, and adverse events were similar in both arms, the companies said in a press release. All patients enrolled in the trial are now being given access to Nexavar.
Articles in this issue
Peptide-Based Breast Ca Vaccines Promising in Early Trials
Diagnostic Dilemma: GI Disease
Imatinib Responses in CML May Take Time
IV Vidaza Approved; Oral Formulation to Be Tested
Study Confirms Avastin Advantage in Advanced NSCLC
Legal Services Should Be a Component of Standard Cancer Care
Mouse Virus Evidence Suggests Viral Basis for Breast Ca
Groups Oppose Ruling on Access to Experimental Drugs
Satellite Allows Digital Mammography Screening for Rural Native Americans
Nexavar Effective in Advanced HCC: Phase III Trial Stopped
H&N Ca Patients With CR to CRT May Not Need Surgery
Two Sets of Researchers Find Herceptin Cost Effective
Family-Based Testing Strategy May Better Detect HNPCC
More 'Promacs,' Worse Outcome
Brachytherapy Balloon Can Be Placed After Final Pathology
Recent Videos
